Knobias ClipReport (8-22-2007)
[?]
Submitted from Knobias ClipReport
MediciNova, Inc. (MNOV) announced results from its Phase Ib clinical trial of MN-221 for the treatment of preterm labor. Target plasma concentrations were achieved with an intravenous priming followed by maintenance infusion dosing paradigm. No significant safety concerns with MN-221 were identified in this clinical trial. The primary objectives of this clinical trial were to determine the pharmacokinetics, safety and tolerability of this infusion regimen of MN-221 in pregnant women. The intravenous formulation of MN-221 is also appropriate for use in emergency facilities.
